Bausch + Lomb Launches EyeGility Inserter for enVista IOLs in the U.S.
BLCO launches EyeGility in the United States, pairing preloaded enVista Aspire lenses with smoother handling, one-handed use and surgical flexibility.
BLCO - Bausch + Lomb Corporation
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$18.33
DETAILS
HIGH:
$21.00
LOW:
$16.00
MEDIAN:
$18.50
CONSENSUS:
$18.33
UPSIDE:
10.36%
Stock News
Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter preloaded IOL delivery system. “The enVista IOL platform has long been appreciated by surgeons for its glistening-free optic and differentiated optic portfolio to suit a wide range of patients,” said Wayne Caulder, vice president and general manager, North America Surgi.
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study did not achieve its primary endpoint of replicating visual function improvements observed in a smaller Phase 1/2a study following 28 days of topical administration. Based on the totality of the data, the company has dec.
Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care
VAUGHAN, Ontario, & MENLO PARK, Calif.--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the creation of Orphia™, a new AI-powered digital health platform built on the belief that eye care providers should spend less time managing disconnected tools and technologies and more time caring for patients. The platform is brand agnostic and designed to serve all eye care providers, r.
Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July 29, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the.
New Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-Confidence
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced new findings from its third annual State of Dry Eye survey, which reveals that the impact of dry eye can extend beyond the burden of physical symptoms, affecting how patients view their emotional health and wellbeing. This year's survey was conducted online by The Harris Poll in May 2026 among 1,000 dry eye suff.
Bausch + Lomb Corporation (BLCO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Bausch + Lomb Corporation (BLCO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care Transcript
Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care Transcript
Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink Triple Care Preservative Free eye drops, which provide instant, long-lasting relief for dry eyes without the use of preservatives and are packaged in a multi-dose bottle. Blink Triple Care Preservative Free is made with the same clinically proven formula as Blink Triple Care, helping red.
Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Chief Medical Officer and Head of Research and Development Yehia Hashad, MD, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL, on Tuesday, June 9, 2026, at 1:20 p.m. ET. A live webcast of the session will be av.
Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2026 annual meeting of shareholders (the “Annual Meeting”) held on May 20, 2026. The detailed results of the vote for the election of directors are set out below: Name For Against Broker Non-Votes Eduardo Alfonso, M.D. 331,573,622 4,244,069 11,452,072 Nathalie Be.
Americans Are Cutting Spending on Everything Except Healthcare. These 2 Medical Device Stocks Under $30 Are Built to Win
With consumer sentiment sitting at 53.3 in March 2026, deep in pessimistic territory, retail investors are hunting for defensive names that can grow even as households tighten budgets.
Bausch + Lomb Announces Second R&D “Teach-in” Webinar
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the second event in its R&D “Teach-in” webinar series that provides deeper insights on the company's robust and differentiated product pipeline. On Monday, June 1, 2026, at 1:00 p.m. ET, Executive Vice President of Research & Development and Chief Medical Officer Yehia Hashad, MD, will be joined by membe.
Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that it will deliver more than 40 scientific data presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting taking place in Denver, CO, May 3-7, 2026. Scientific posters and papers will highlight the results of various studies across the company's broad portfolio of products.
Bausch + Lomb Corporation (BLCO) Q1 2026 Earnings Call Transcript
Bausch + Lomb Corporation (BLCO) Q1 2026 Earnings Call Transcript
Bausch + Lomb (BLCO) Surpasses Q1 Earnings and Revenue Estimates
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.07 per share a year ago.
Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2026 financial results. “We're doing exactly what we said we would: driving sustainable growth and margin expansion, improving how we sell and operate and continuing to invest in a pipeline that will carry us forward,” said Brent Saunders, chairman and CEO, Bausch + Lomb. Select Company Highlig.
Bausch + Lomb Releases 2025 Sustainability Impact Report
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the release of its 2025 Sustainability Impact Report, outlining progress against its environmental, social and governance priorities and introducing The Broader Perspective, the company's sustainability framework designed to guide future action and accountability. Anchored in the belief that seeing the full pict.
Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its one-of-a-kind ONE by ONE Recycling program, created in collaboration with international recycling leader TerraCycle®, has collected and recycled a total of 119,715,074 units, or 724,922 pounds, of used contact lenses, eye care and lens care materials in the United States – the equivalent of about five backya.
Comparing Biodesix (NASDAQ:BDSX) & Bausch + Lomb (NYSE:BLCO)
Biodesix (NASDAQ: BDSX - Get Free Report) and Bausch + Lomb (NYSE: BLCO - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation. Insider and Institutional Ownership 21.0% of Biodesix shares
Price Targets
Bausch + Lomb price target raised to $17 from $16 at Evercore ISI
$17.00
(was $17.06)
Evercore ISI
Bausch + Lomb price target lowered to $16 from $18 at Deutsche Bank
$16.00
(was $15.54)
Deutsche Bank
Bausch + Lomb price target raised to $20 from $17 at H.C. Wainwright
$20.00
(was $17.64)
H.C. Wainwright
Bausch + Lomb price target raised to $16 from $15 at Stifel
$16.00
(was $17.67)
Stifel Nicolaus
Bausch + Lomb price target raised to $18 from $15 at Deutsche Bank
$18.00
(was $17.67)
Deutsche Bank
Bausch + Lomb price target raised to $20 from $17 at Barclays
$20.00
(was $17.67)
Barclays
Bausch + Lomb price target raised to $15 from $14 at Stifel
$15.00
(was $17.25)
Stifel Nicolaus
Bausch + Lomb price target raised to $21 from $19 at RBC Capital
$21.00
(was $16.87)
RBC Capital
Bausch + Lomb price target raised to $19 from $17 at Goldman Sachs
$19.00
(was $17.30)
David Roman
·
Goldman Sachs
Bausch + Lomb downgraded to In Line from Outperform at Evercore ISI
$18.00
(was $16.58)
Vijay Kumar
·
Evercore ISI
Bausch + Lomb upgraded to Overweight at Morgan Stanley on pipeline potential
$21.00
(was $16.56)
Morgan Stanley
Bausch & Lomb Corp. (BLCO) PT Raised to $19 at RBC Capital
$19.00
(was $15.69)
Douglas Miehm
·
RBC Capital
Bausch & Lomb Corp. (BLCO) PT Raised to $20 at Jefferies
$20.00
(was $15.69)
Zachary Weiner
·
Jefferies
Bausch + Lomb price target raised to $17 from $16 at H.C. Wainwright
$17.00
(was $15.14)
H.C. Wainwright
Bausch + Lomb price target raised to $17 from $16 at Barclays
$17.00
(was $15.14)
Barclays
Bausch + Lomb price target raised to $16 from $15 at Wells Fargo
$16.00
(was $15.47)
Wells Fargo
Bausch + Lomb initiated with a Neutral at Goldman Sachs
$16.00
(was $15.07)
Goldman Sachs
Bausch + Lomb price reaction to recall 'likely overdone,' says RBC Capital
$18.00
(was $15.00)
RBC Capital
Morgan Stanley Downgrades Bausch & Lomb Corp. (BLCO) to Equalweight
$19.00
(was $19.28)
Patrick Wood
·
Morgan Stanley
Bausch & Lomb Corp. (BLCO) PT Raised to $23 at H.C. Wainwright
$23.00
(was $20.44)
Yi Chen
·
H.C. Wainwright